{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:59:56Z","timestamp":1790665196565,"version":"4.1.0"},"reference-count":22,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"V Foundation Translational Award","award":["T2018-011"],"award-info":[{"award-number":["T2018-011"]}]},{"name":"V Foundation Translational Award","award":["T2018-011"],"award-info":[{"award-number":["T2018-011"]}]},{"name":"V Foundation Translational Award","award":["T2018-011"],"award-info":[{"award-number":["T2018-011"]}]},{"name":"CPRIT funding","award":["RP110771"],"award-info":[{"award-number":["RP110771"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P50196516"],"award-info":[{"award-number":["P50196516"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50196516"],"award-info":[{"award-number":["P50196516"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1P30 CA142543"],"award-info":[{"award-number":["1P30 CA142543"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0607-z","type":"journal-article","created":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T21:02:32Z","timestamp":1559509352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response"],"prefix":"10.1136","volume":"7","author":[{"given":"Joseph","family":"Vento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Mulgaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layton","family":"Woolford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kien","family":"Nham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Diaz","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee M.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiankai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"issue":"1","key":"607_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1634\/theoncologist.2011-0227","volume":"17","author":"B Shuch","year":"2012","unstructured":"Shuch B, et al. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist. 2012;17(1):46\u201354.","journal-title":"Oncologist"},{"issue":"2","key":"607_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11523-015-0392-7","volume":"11","author":"R Iacovelli","year":"2016","unstructured":"Iacovelli R, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. 2016;11(2):143\u20138.","journal-title":"Target Oncol"},{"issue":"19","key":"607_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"14","key":"607_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"key":"607_CR5","doi-asserted-by":"crossref","unstructured":"McDermott DF, M.R., Rini BI, et al. CheckMate 214 retrospective analyses of NIVO+IPI or SUN in IMDC intermediate\/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. in 17th International Kidney Cancer Symposium. 2018. Miami, FL, USA.","DOI":"10.1200\/JCO.2019.37.15_suppl.4513"},{"key":"607_CR6","unstructured":"Tannir, N.M. CheckMate 214 Retrospective Analyses of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate\/Poor-Risk Patient With Previously Untreated Advanced Renal Cell Carcinoma With Sarcomatoid Features. In Kidney Cancer International Symposium. 2018. Miami, FL."},{"issue":"8","key":"607_CR7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.prp.2018.06.003","volume":"214","author":"JI Lopez","year":"2018","unstructured":"Lopez JI, et al. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. Pathol Res Pract. 2018;214(8):1110\u20134.","journal-title":"Pathol Res Pract"},{"issue":"34","key":"607_CR8","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794\u20139.","journal-title":"J Clin Oncol"},{"issue":"137","key":"607_CR9","doi-asserted-by":"publisher","first-page":"137ra75","DOI":"10.1126\/scitranslmed.3003643","volume":"4","author":"S Sivanand","year":"2012","unstructured":"Sivanand S, et al. A validated Tumorgraft model reveals activity of Dovitinib against renal cell carcinoma. Sci Transl Med. 2012;4(137):137ra75.","journal-title":"Sci Transl Med"},{"key":"607_CR10","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/nprot.2014.108","volume":"9","author":"A Pav\u00eda-Jim\u00e9nez","year":"2014","unstructured":"Pav\u00eda-Jim\u00e9nez A, Tcheuyap VT, Brugarolas J. Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing. Nat Protoc. 2014;9:1848.","journal-title":"Nat Protoc"},{"issue":"2_suppl","key":"607_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/jco.2016.34.2_suppl.532","volume":"34","author":"Raquibul Hannan","year":"2016","unstructured":"Hannan R, et al. Phase II trial of high-dose interleukin-2 (IL-2) and stereotactic radiation therapy (SABR) for metastatic clear cell renal cell carcinoma (ccRCC): interim analysis. J Clin Oncol. 2016;34(2_suppl):532\u20132.","journal-title":"Journal of Clinical Oncology"},{"key":"607_CR12","unstructured":"National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, U.S Department of Health and Human Services. 2017.\n                    https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"issue":"3","key":"607_CR13","first-page":"e143","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The lancet. Oncology. 2017;18(3):e143\u201352.","journal-title":"Oncology"},{"issue":"1","key":"607_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nucmedbio.2012.08.004","volume":"40","author":"MA Deri","year":"2013","unstructured":"Deri MA, et al. PET imaging with (89) Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013;40(1):3\u201314.","journal-title":"Nucl Med Biol"},{"issue":"4","key":"607_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nprot.2010.13","volume":"5","author":"MJWD Vosjan","year":"2010","unstructured":"Vosjan MJWD, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protocols. 2010;5(4):739\u201343.","journal-title":"Nat Protocols"},{"key":"607_CR16","doi-asserted-by":"crossref","unstructured":"Zeglis, B.M. and J.S. Lewis, The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies. 2015(96): p. e52521.","DOI":"10.3791\/52521"},{"issue":"1","key":"607_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","volume":"72","author":"T Lindmo","year":"1984","unstructured":"Lindmo T, et al. Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72(1):77\u201389.","journal-title":"J Immunol Methods"},{"issue":"12","key":"607_CR18","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24(12):1852.","journal-title":"Nat Med"},{"key":"607_CR19","doi-asserted-by":"publisher","first-page":"19740","DOI":"10.1038\/srep19740","volume":"6","author":"C-T Wu","year":"2016","unstructured":"Wu C-T, et al. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep. 2016;6:19740.","journal-title":"Sci Rep"},{"issue":"2","key":"607_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, et al. Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687\u201395.","journal-title":"J Clin Invest"},{"issue":"3","key":"607_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.imlet.2004.05.007","volume":"94","author":"P Youngnak-Piboonratanakit","year":"2004","unstructured":"Youngnak-Piboonratanakit P, et al. The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. Immunol Lett. 2004;94(3):215\u201322.","journal-title":"Immunol Lett"},{"issue":"3","key":"607_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.oraloncology.2014.11.014","volume":"51","author":"P Ritprajak","year":"2015","unstructured":"Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 2015;51(3):221\u20138.","journal-title":"Oral Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0607-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:44:27Z","timestamp":1601041467000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0607-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0607-z","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"8 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All murine tumorgraft experiments were executed in compliance with institutional guidelines after approval of the institutional review board with protocol numbers 2015\u2013100932, \u201cExploring RCC Genetics and Treatment Using Mouse Models,\u201d and 2016\u2013101458-CORE, \u201cPET\/CT Imaging of Normal or Diseased Mice with Radiotracers Developed or Produced by the Cyclotron and Radiochemistry Facility.\u201d The mice described implanted are 4\u20136\u2009week old male NOD-SCID (NOD.CB17-Prkdc\n                      \n                      ) mice.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and clinical images was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"144"}}